Medicaid

Hazel Health Announces Marianna Spanos as New Chief Operating Officer & Welcomes Jeremy Delinsky, Iyah Romm, and Jessie Woolley-Wilson to the Board of Directors

SAN FRANCISCO, Feb. 19, 2025 /PRNewswire/ -- Hazel Health, the nation's largest school-centered telehealth provider, today welcomed Marianna Spanos as Chief...

CHAP: COMMUNITY HEALTH ACCREDITATION PARTNER AWARDS MAXWELL HEALTHCARE ASSOCIATES’ nanaBEREAVEMENT PRODUCT ITS “CHAP VERIFIED” STATUS

SHOREVIEW, Minn., Feb. 19, 2025 /PRNewswire/ -- Maxwell Healthcare Associates (MHA) is pleased to announce that nanaBEREAVEMENT, a tech-enabled bereavement...

Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD

First U.S. patients being treated with Lenmeldy™ (atidarsagene autotemcel) in a commercial setting; other launch efforts progressing well following Food...

RAINFALL HEALTH ANNOUNCES INAUGURAL COMMITTEE WITH HEALTHCARE LEADERS IN AN UNPRECEDENTED MOVE TOWARD STANDARDIZING HEALTH CARE DELIVERY ACROSS THE COUNTRY

SAN FRANCISCO, Feb. 10, 2025 /PRNewswire/ -- The Advisory Committee provides strategic guidance to promote equitable and accessible healthcare. By...

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen...

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

Nicolas S. Piuzzi, MD, Presented Kappa Delta Young Investigator Award for Research on Employing Data Analytics to Improve Patient Outcomes

ROSEMONT, Ill., Feb. 7, 2025 /PRNewswire/ -- Nicolas S. Piuzzi, MD, was recognized as the 2025 Kappa Delta Young Investigator Award...

error: Content is protected !!